Key facts
- Yangzhou Shizhiyuan’s last known valuation is $40.4M (Mar 2025).
- Notable investors include SDIC Chuangyi, Shanghai Shen Lian.
- Status: Acquired/Merged (Operating Subsidiary).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Yangzhou Shizhiyuan
- ·The full record, as it builds
Funding rounds
No funding rounds for Yangzhou Shizhiyuan are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yangzhou Shizhiyuan
Manufacturer of therapeutic monoclonal antibody drugs intended for biopharmaceutical manufacturers and research institutions. The company specializes in monoclonal antibodies and anti-allergic monoclonal antibodies along with de-fucosylation technology, thereby enabling clients to optimize cell-dependent toxic effects, target efforts, improve existing products, and solve the problem of poor efficacy of some monoclonal antibodies.
- Sector
- Healthcare
- HQ
- Yangzhou, China
- Founded
- 2018
- Website
- ubpyz-cmo.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Yangzhou Shizhiyuan doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yangzhou Shizhiyuan shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yangzhou Shizhiyuan in its N-PORT filings yet. We sweep new filings monthly.